Griffin Health Nuclear Medicine offers a groundbreaking treatment option for patients with advanced prostate cancer with its Pluvicto® Theranostics Program.
Pluvicto is an FDA-approved radioligand therapy for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. This therapy targets prostate-specific membrane antigen (PSMA)-positive cancer cells, delivering a radioactive payload directly to the tumor, while minimizing damage to surrounding healthy tissue.
Person-centered Prostate Cancer Care
The Griffin Health Pluvicto Theranostics program is designed to expand access to a cutting-edge, targeted radioligand therapy, enhance coordination of care for men with advanced prostate cancer, and improve quality of life and potentially extend survival for eligible patients. It offers a person-centered multidisciplinary care model, including physicians in Nuclear Medicine, Medical Oncology, and Radiation Oncology as well as Nuclear Medicine Technologists, nursing staff, and patient navigation teams to ensure safe, effective, and personalized treatment delivery. As part of a continuous care model, Griffin Health offers PSMA PET/CT imaging for patients to confirm their eligibility before beginning therapy.
Contact Us
Griffin is now accepting referrals for its Pluvicto Theranostics program. Referring providers can contact the Nuclear Medicine Department at 203-732-7271 for more information and orders can be faxed to Central Scheduling at 203-732-1559.